Cagrilintide

Description

Introducing Cagrilintide 5mg, a novel amylin analog under investigation for its potential role in appetite regulation, weight management, and metabolic health. Cagrilintide is designed to mimic and enhance the effects of the naturally occurring hormone amylin, which plays a key role in satiety signaling and post-meal glucose control. By binding to amylin receptors, this compound has been shown in research models to slow gastric emptying, reduce food intake, and improve glycemic profiles. It is being explored both as a monotherapy and in combination with other metabolic agents for its synergistic effects on body weight reduction and energy balance. Cagrilintide represents a promising advancement in the study of obesity and metabolic disorders, offering researchers a new pathway for investigating long-term weight control strategies.

Features

• Amylin analog studied for appetite suppression and satiety enhancement
• Investigated for effects on gastric emptying and postprandial glucose regulation
• Explored in combination therapies for greater weight loss potential
• Relevant in research on obesity, metabolic syndrome, and insulin resistance
• Potential role in sustained energy balance and reduced caloric intake

Specs

• Volume: 10 MG
• Purity: Research Grade
• Composition: Cagrilintide (Amylin Analog)
• Molecular Weight: Approximately 4020 Da
• Stability: Stable under standard laboratory storage conditions